Company intelligence / Profile preview
Küleon
Seattle, Washington, United Stateskuleonbio.com ↗
- Ownership
- Private
- Employees
- ~1
- Development stage
- Other
01
Overview
Küleon has developed the first known trifunctional serotonergic small molecule KB-128, which is a full agonist at 5-HT2C and a full antagonist at 5-HT2A and 5-HT2B. KB-128 has completed initial ADME/PK and toxicology studies with strong results and is advancing through IND-enabling studies. No clinical results yet released; company states high selectivity, low off-target activity, and promising pharmacokinetic properties.[2][4]
- Therapeutic areas
- ImmunologyNeurologyEndocrinologyPsychiatry
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Küleon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Küleon.